Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan

 Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan

Shots:

  • The filing is based on the results from the P-III IMpower010 study assessing Tecentriq (1200mg, IV) vs BSC in 1,005 patients in a ratio (1:1) with Stage IB-IIIA NSCLC, following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
  • Results: 34% reduction in risk of disease recurrence or death in people with PD-L1 expression compared with BSC while safety data were consistent with its known safety profile & no new safety signals were observed
  • Additionally, ~50% of patients with early-stage lung cancer experience relapse following surgery. Tecentriq is the first cancer immunotherapy that showed efficacy for the adjuvant treatment of NSCLC

Click here to read full press release/ article | Ref: Chugai | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post